Publications by authors named "David Lebwohl"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

112,317

Total Likes

8,142

Extended Reach

2,879,298

Social Features

309
N
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Julian D Gillmore, Ed Gane, Jörg Täubel, Björn Pilebro, Andoni Echaniz-Laguna, David Lebwohl

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Based Therapy for Hereditary Angioedema.
Danny M Cohn, Padmalal Gurugama, Markus Magerl, Constance H Katelaris, David Launay, David Lebwohl

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.
Marianna Fontana, Scott D Solomon, Jessica Kachadourian, Liron Walsh, Ricardo Rocha, David Lebwohl

N Engl J Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 In Vivo Gene Editing of for Hereditary Angioedema.
Hilary J Longhurst, Karen Lindsay, Remy S Petersen, Lauré M Fijen, Padmalal Gurugama, David Lebwohl

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.
Julian D Gillmore, Michael L Maitland, David Lebwohl

N Engl J Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
Evgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Mouna Akacha

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Stacie Ittershagen, Solveig Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, David Lebwohl

Curr Hematol Malig Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, David Lebwohl

N Engl J Med· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Gabriel N Hortobagyi, David Chen, Martine Piccart, Hope S Rugo, Howard A Burris, David Lebwohl

J Clin Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Atsushi Ohtsu, Jaffer A Ajani, Yu-Xian Bai, Yung-Jue Bang, Hyun-Cheol Chung, David Lebwohl

J Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Denise A Yardley, Shinzaburo Noguchi, Kathleen I Pritchard, Howard A Burris, José Baselga, David Lebwohl

Adv Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
David Lebwohl, Ozlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth

Ann N Y Acad Sci· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Michael Gnant, Jose Baselga, Hope S Rugo, Shinzaburo Noguchi, Howard A Burris, David Lebwohl

J Natl Cancer Inst· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
John J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, Bernard A Zonnenberg, Michael Frost, David Lebwohl

Lancet· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
David Neal Franz, Elena Belousova, Steven Sparagana, E Martina Bebin, Michael Frost, David Lebwohl

Lancet· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
José Baselga, Mario Campone, Martine Piccart, Howard A Burris, Hope S Rugo, David Lebwohl

N Engl J Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Marianne E Pavel, John D Hainsworth, Eric Baudin, Marc Peeters, Dieter Hörsch, David Lebwohl

Lancet· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Michael I Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C Gatter, Tanja Trarbach, David Lebwohl

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Eric Van Cutsem, Emilio Bajetta, Juan Valle, Claus-Henning Köhne, J Randolph Hecht, David Lebwohl

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
J Randolph Hecht, Tanja Trarbach, John D Hainsworth, Pierre Major, Elke Jäger, David Lebwohl

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research and innovation in the development of everolimus for oncology.
David Lebwohl, George Thomas, Heidi A Lane, Terence O'Reilly, Bernard Escudier

Expert Opin Drug Discov· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus for advanced pancreatic neuroendocrine tumors.
James C Yao, Manisha H Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M Wolin, David Lebwohl

N Engl J Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
Joachim Drevs, Michael Medinger, Klaus Mross, Stefan Fuxius, Juergen Hennig, David Lebwohl

Anticancer Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
James C Yao, Catherine Lombard-Bohas, Eric Baudin, Larry K Kvols, Philippe Rougier, David Lebwohl

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis